VBI Vaccines — SciVac Therapeutics — Investor Presentation (May 2016)
32 slides from VBI Vaccines's investor presentation, May 18, 2016
Slide 1: VBI Vaccines May 2016
Willy, “> VBI VACCINES Sadiliel li 3 7a NASDAQ: VBIV . TSX: VBV MAY 2016
Slide 2: Cautionary Statement Regarding Forward-Looking Information
Cautionary Statement Regarding Forward-Looking Information Certain statements in this presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation (collective
Slide 3: Leading Immunology Innovation in Significant Markets with High Unmet Need
Leading Immunology Innovation in Significant Markets with High Unmet Need PIPELINE + Hepatitis B Vaccine: 3° generation vaccine targeting non-responders to SoC TECHNOLOGY PLATFORMS + Enveloped Virus-Like Particle (“eVLP”) platform closely mimics viruses and induces potent and durable immune response
Slide 4: Recent Key Achievements
Recent Key Achievements April 2015 — May 2016 May 2016 Y closed SciVac Therapeutics Transaction February Y entered into LPV™ GSK collaboration October 2015 V seacunesnnent of GBM candidate V announcement of RSV program and NRC-IRAP grant of $350,000 CAD August 20 Y closed $6.29MM PIPE Y entered into
Slide 5: VBI Vaccines Pipeline
VBI Vaccines Pipeline Multiple Opportunities in Infectious Disease and Oncology Research Lead Preclinical Phase! Phase Il Phase Ill eVLP Platform Infectious Disease HBV (sci-B-Vac) (Licensed in 15 countries) | CMV (vai-15014) | searon ate RSV | | Immuno-Oncology GBM xXx #8 . | Undisclosed = Undisclo
Slide 6: Near-Term Goals for Value Creation
Near-Term Goals for Value Creation 1 ci ™ global development plan oy wy Advancement of congenital CMV vaccine candidate, VBI-1501A, into Phase 1 clinical trials fy i Expansion of eVLP platform into Immuno-Oncology indications 7" } Development of additional eVLP Infectious Disease programs to be anno
Slide 7: Sci-B-Vac Overview
Sci-B-Vac™ Overview ONLY COMMERCIAL HBV VACCINE TO MIMIC ALL 3 VIRAL SURFACE ANTIGENS — ALREADY SAFELY USED IN 300,000+ PATIENTS * Sci-B-Vac™ achieves rapid onset of protection, with high levels of anti-HBV antibodies (HBsAb), at a lower dosage than competing vaccines 2N GENERATION VACCINES Viral an
Slide 8: Excerpt of Existing Sci-B-Vac Data
SS lllE—EE[{lS== Excerpt of Existing Sci-B-Vac™ Data * Over 20 clinical studies have been completed in >4,500 patients * Several Phase II and Phase III studies have been conducted — results of which include: fac™ SPR 1* Generation HBV Va' Population Si 98% - month 6, post 2" injection; N=105 Young a
Slide 9: Near-Term Goals for Value Creation
Near-Term Goals for Value Creation fry Determination of Sci-B-Vac™ global ad development plan fy is} ital CMV vaccine into Phase 1 clinical trials rams i Expansion of eVLP platform into Immuno- Oncology indications 7" } Development of additional eVLP Infectious Disease programs to be announced f. AX
Slide 10: eVLPs are a 3rd-Generation Class of Synthetic Vaccines
eVLPs are a 3'-Generation Class of Synthetic Vaccines = eVLPs are the same size and structure as enveloped viruses; present antigens in their natural state for an improved immune response = The foundation of the eVLP Platform is a stable, protein-based core on which additional vaccine antigens of in
Slide 11: eVLP Presentation Improves CMV Vaccine Potency
eVLP Presentation Improves CMV Vaccine Potency Presentation of gB antigen in an eVLP improves relevant functional CMV neutralizing responses relative to recombinant gB protein. PRECLINICAL RESULTS Neutralizing antibody titers for mice immunized _ . with comparable doses of Recombinant gB of = Neutra
Slide 12: Congenital CMV is a Leading Public Health Priority
— EEE» ——>yy_—_—>=>== Congenital CMV is a Leading Public Health Priority = Each year, approximately 5,000 U.S. infants will develop permanent problems due to CMV, some of them severe, including deafness, blindness, and developmental delays = Inthe U.S., the direct economic costs of CMV infection exc
Slide 13: VBI-1501A Stimulates CMV Neutralizing Antibodies
VBI-1501A Stimulates CMV Neutralizing Antibodies Comparable to Natural Levels of Immunity NEUTRALIZING ANTIBODY TITERS OF RABBITS 28 DAYS AFTER A SECOND VACCINATION WITH VBI-1501A, COMPARED TO CMV+ DONORS IN TWO 10,000 1,000 100 10 Endpoint nAb Titer (1/x) CLINICALLY RELEVANT, CMV-SUSCEPTIBLE CELL L
Slide 14: VBI-1501A CMV Candidate: Phase I Trial Design
SS lllE—EE[{lS== VBI-1501A CMV Candidate: Phase | Trial Design Benchmarking against natural immunity may allow for human proof of concept in a sufficiently powered Phase | clinical trial. ANTICIPATED TRIAL DESIGN = Estimated Start: H1 2016 Target Population: ~125 CMV-Negative Healthy Adults (18-40 y
Slide 15: Near-Term Goals for Value Creation
Near-Term Goals for Value Creation “ Determination of Sci-B-Vac™ global ad development plan 2""~ Advancement of congenital CMV vaccine candidate, VBI-1501A, into Phase 1 clinical trials C Ne rams o ‘m into Immuno- 7" } Development of additional eVLP Infectious Disease programs to be announced f. AX
Slide 16: Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate
Therapeutic GBM Candidate Builds on Prophylactic CMV Candidate (VBI-1501A) by Adding an Internal pp65 Protein to Elicit a Th1 Response gB Envelope pp65 Vv ‘NeoAntigen’ V | ‘NeoAntigen’ x? : Bivalent — pp65 for Therapeutic Ilmmuno- Monovalent gB for Attributes Prophylaxis oncoleey Present antigen in
Slide 17: Poor Immunogenicity of Traditional Tumor-Associated Antigens
SS lllE—EE[{lS== Poor Immunogenicity of Traditional Tumor-Associated Antigens (TAAs) has Limited Past Therapeutic Cancer Vaccines IMMUNOGENICITY “Foreign” Viral TAAS Neoantigens “Self” TAAs LOW > HIGH VIRAL CMV ANTIGENS ARE OVER-EXPRESSED (>90%) IN MULTIPLE SOLID TUMORS, INCLUDING: = Glioblastoma (G
Slide 18: CMV as a Foreign Viral TAA
CMV as a “Foreign” Viral TAA CLINICAL EVIDENCE SUGGESTS CMV VACCINATION CAN BE SUCCESSFUL (DUKE DATA)?* = Dendritic cell priming combined with CMV vaccination significantly extended overall survival of GBM patients relative to SoC = Three patients in investigational cohort (n=6) did not progress and
Slide 19: Bivalent gB/pp65 eVLPs Stimulate Both CD4+ and CD8+ Human T cell Responses
Bivalent gB/pp65 eVLPs Stimulate Both CD4* and CD8* Human T cell Responses Ex Vivo Frequency of Response (%) CD4*IFN-y*T Cells CD8*IFN-y* T Cells Bivalent g8/pp65 eVLPs were used to stimulate freshly isolated PBMCs from 8 healthy subjects. Responses reflect substraction of background responses to st
Slide 20: VBI GBM Vaccine Elicits Strong Th1 Immunity & Mobilizes Dendritic Cells
VBI GBM Vaccine Elicits Strong Th1 Immunity & Mobilizes Dendritic Cells when Adjuvanted with GM-CSF EVLP STIMULATION ELICITS DESIRED IMMUNO-PHENOTYPE — CORRELATES WITH CLINICAL BIOMARKER CCL3 IDENTIFIED IN DUKE STUDY (MITCHELL DA(2015) NATURE 519, 366-369) = ° ~& gB/pp65 eVLPs ~® eVLPs+GM-CSF 104 10
Slide 21: Early Data from Columbia Collaboration
Early Data from Columbia Collaboration GBM Patient PBMCs Respond to Bivalent eVLP & GMCSF Stimulation ~@ gB/pp65 eVLPs ~@ eVLPs+GM-CSF oo 10 —“ Healthy PBMCs GBM PBMCs CCL3 Secretion (pg/ml) 3 Bivalent gB/pp65 eVLPs were used to stimulate frozen/ thawed PBMCs from 4 healthy subjects and 4 primary GB
Slide 22: VBI GBM Candidate Expected Timeline
VBI GBM Candidate Expected Timeline COMPLETED MILESTONES v Q1 2016: Pre-clinical IND-enabling data Y Q12016: Clinical Advisory Meeting REMAINING MILESTONES TO PH I START Q H12016: Pre-IND meeting with FDA H2 2016: GMP clinical trial materials manufacturing H2 2016: IND Submission H2 2016: Investigat
Slide 23: Near-Term Goals for Value Creation
Near-Term Goals for Value Creation Z “ Determination of Sci-B-Vac™ global ad development plan 2""~ Advancement of congenital CMV vaccine candidate, VBI-1501A, into Phase 1 clinical trials C Ne rams i Expansion of eVLP platform into Immuno- Oncology indications 7" } Development of additional eVLP Inf
Slide 24: LPV Platform Overview
LPV™ Platform Overview Enables thermostable vaccine delivery, which is expected to increase vaccine access and preserve safety and efficacy IMPROVES ACCESS PRESERVES POTENCY UNLOCKS VALUE Enables safe storage and transfer outside of the refrigerator / freezer “cold chain” Improved stability enables
Slide 25: LPV Platform Proof of Concept
LPV™ Platform Proof of Concept Proprietary formulation of lipids preserves stability and potency for multiple classes of vaccines and biologics. PROOF OF CONCEPT = Protein subunit vaccine (Influenza) = 12 Months at 40° C = Live Biologic Vaccine (MMR) = 8 Weeks at 37°C =" Monoclonal Antibody Therapeu
Slide 26: LPV Development Plan
LPV™ Development Plan The LPV™ Platform has the potential to confer thermostability to vaccines and biologics under development. COMMERCIALIZATION Entered into a broad research J collaborations with Sanofi Pasteur F and GSK to apply LPV™ technology SANOFI to further the development of key vaccine ca
Slide 27: Expected Upcoming Milestones
Expected Upcoming Milestones KEY NEAR-TERM ANTICIPATED VALUE DRIVERS = H1 2016: Pre-IND meeting with FDA regarding therapeutic GBM vaccine candidate = H1 2016: Start Phase | clinical studies for CMV vaccine candidate = H2 2016: Determine Sci-B-Vac™ regulatory and clinical development path = H1 2017:
Slide 28: Peer Comparison
Peer Comparison SAMPLE OF NASDAQ/NYSE VACCINE & 1O COMPANIES Dev’t Share Price Market Cap Company icker Date Publi Lead Programs yy 3 Stage ($u.s.) ($U.s.) Therapeutic HSV-2 Genocea GNCA 2014 PKCUCRESe Phil $3.62 $102.4M HPV, Phill Advaxis ADXS 2005 PSA, Phifil $7.01 $239.1M HER2 Phi Immune Design i
Slide 29: Experienced Leadership
Experienced Leadership Vaccine development, commerc ation, and financing expertise. DR. STEVEN GILLIS, CHAIRMAN OF THE BOARD + immunologist and investor with track record of blockbuster drugs and visionary corporate development success. = Founder of Immunex, the developer of Enbrel, a $7B/year landm
Slide 30: VBI Vaccines Board of Directors
VBI Vaccines Board of Directors Dr. Steve Gillis is @ Ph.D. immunologist by training with ‘expertise in molecular and tumor immunology. Previously, he served as the Founder and CEO of Corixa, which was acquired in 2005 by GSK for $300M. Prior to Corixa, Dr. Gillis was Founder ‘and Director of Immune
Slide 31: VBI Vaccines Global Footprint
VBI Vaccines Global Footprint HEADQUARTERS —- CAMBRIDGE, MA = CEO, CSO, CTO, CFO + 4 FTEs = Central location in biotechnology hub RESEARCH OPERATIONS — OTTAWA, CANADA = ~20FTEs = World-class R&D team and facility MANUFACTURING FACILITY — REHOVOT, ISRAEL = ~SOFTEs = GMP manufacturing facility for the
Slide 32: VBI Vaccines Inc. contact details
VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com NASDAQ: VBIV | TSX: VBV
SciVac Therapeutics — Investor Presentation (May 2016) on 6ix